H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Nkarta to $10 from $16 and keeps a Buy rating on the shares. The analyst believes a lot of uncertainty persists as the company optimizes doses and dosing regimens for both NKX101 and NKX019, along with next steps for its programs, but still thinks both therapies have been shown to be active.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NKTX:
- Nkarta upgraded to Strong Buy from Outperform at Raymond James
- Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
- Nkarta opens new cohort in Phase 1 study of NKX019
- Nkarta announces cost containment measures to extend cash runway
- Nkarta receives FDA clearance of IND application for NKX019
